Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease

Movement Disorders

Volumn 21, Issue 11, 2006, Pages 1998-2001

  Zesiewicz, Theresa A ^a,b   Sullivan, Kelly L ^a,b   Hauser, Robert A ^a,b   Sanchez Ramos, Juan ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Chorea; Huntington's disease; Keppra; Levetiracetam

Indexed keywords

ALPRAZOLAM; CELECOXIB; DONEPEZIL; ETIRACETAM; FUROSEMIDE; GABAPENTIN; OLANZAPINE; OXYBUTYNIN; PAROXETINE; RISPERIDONE; TRAZODONE;

ADULT; ARTICLE; BRADYKINESIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MUSCLE RIGIDITY; OPEN STUDY; PARKINSONISM; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; REPEATED DRUG DOSE; SCORING SYSTEM; SOMNOLENCE; TREATMENT OUTCOME; TREMOR;

ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PILOT PROJECTS; PIRACETAM; SEVERITY OF ILLNESS INDEX;

EID: 33845206589     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21061     Document Type: Article

References (13)

1. Graveland GA, Williams RS, DiFiglia A Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985;227:770-773.
2. Huntington Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's Disease chromosomes. Cell 1993;72:971-983.
3. Caine ED, Shoulson I. Psychiatric syndromes in Huntington's disease. Am J Psychiatry 1983;140:728-733.
4. Tyler A, Scourfield J, Morris A Management and therapy of Huntington's Disease. In: Harper PS, editor. Huntington's Disease. Philadelphia: WB Saunders; 1991. p 161-200.
5. Barr AN, Fischer JH, Koller WC, et al. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 1988;38:84-88.
6. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242.
7. Shorvon SID, Lowenthal A, Janz D, et al. Multi-center double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000;41:1179-1186.
8. Hill MP, Bezard E, McGuire SG, et al. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 2003;18:1301-1305.
9. Bezard E, Hill MP, Crossman AR, et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 2004;485:159-164.
10. Hill MP, Bezard E, McGuire SG, et al. Novel antiepileptic drug levetiracetarn decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 2003;18:1301-1305.
11. Bourke D, Druckenbrod RW. Possible association between donepezil and worsening Parkinson's disease. Ann Pharmacother 1998; 32:610-611.
12. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8.
13. Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calfigaro DO, Mckinzie DL. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1125-1143.